Navigation Links
PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
Date:8/9/2011

periods (which excludes the special items referenced above) was $6.1 million, or $0.10 per diluted share in the quarter ended June 30, 2011, and was $19.1 million, or $0.32 per diluted share in the quarter ended June 30, 2010.  Using adjusted numbers in both periods, adjusted net income in the current quarter declined by 68.2% year-over-year, and adjusted earnings per diluted share declined by 68.8%.

Consolidated service revenue for the fourth quarter of Fiscal Year 2011 was $232.8 million in Clinical Research Services (CRS), $35.2 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $42.5 million in Perceptive Informatics, Inc. (Perceptive).

On a GAAP basis for the full fiscal year ended June 30, 2011, consolidated service revenue was $1,212.1 million versus $1,131.0 million in the prior year, a year-over-year increase of 7.2%.  Excluding the positive impact of foreign exchange of approximately $3.8 million in Fiscal Year 2011, revenue increased 6.8% from the prior year.  For Fiscal Year 2011, GAAP operating income was $81.6 million, or 6.7% of consolidated service revenue, compared with GAAP Fiscal Year 2010 operating income of $83.1 million, or 7.3% of consolidated service revenue.  GAAP operating income declined 1.8% year-over-year.  

Excluding the impact of special items, as detailed in the attached financial tables in both periods, adjusted operating income was $90.1 million, or 7.4% of consolidated service revenue in Fiscal Year 2011, compared with adjusted operating income of $103.5 million, or 9.1% of consolidated service revenue, in Fiscal Year 2010.  On this adjusted basis, operating income in Fiscal Year 2011 declined 12.9% year-over-year.  Net income on a GAAP basis for Fiscal Year 2011 was $48.8 million, or $0.81 per diluted share, compared with GAAP net income of $41.5 million, or $0.71 per diluted share, in Fiscal Year 2010.  On a GAAP basis, net income in the curr
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2011 Earnings Release and Conference Call
3. PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference
4. PAREXEL Invites Public to Listen to Live Webcast of Its Investor Day June 2, 2011
5. PAREXEL Reports Third Quarter Fiscal Year 2011 Financial Results
6. Key Presentations Announced for Landmark Future of Biosimilars Event Co-Sponsored by DIA and FDLI, Co-Chaired by Merck and PAREXEL
7. PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market
8. PAREXEL Announces Date of Third Quarter Fiscal Year 2011 Earnings Release and Conference Call
9. PAREXEL Experts To Address Best-Practice Strategic Partnership Models To Increase Operating Efficiency, Development Effectiveness at Partnerships in Clinical Trials
10. PAREXEL Experts to Present Advanced Approaches to Accelerate Development, Maximize Product Value at DIA EuroMeeting
11. PAREXEL International to Present at Raymond James Investors Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... 2014   NuVascular Technologies, Inc. is ... medical devices that help millions. ... cutting-edge nanotechnology that would target serious conditions such ... The platform technology was developed over a ... in funding obtained from National Institutes of Health. ...
(Date:10/16/2014)... Oct. 16, 2014 Ninety percent of children ... relapsed multiple times or failed to respond to standard ... cellular therapy, CTL019, developed at the Perelman School of ... today in The New England Journal ... builds on preliminary findings presented at the American Society ...
(Date:10/16/2014)... Oct. 16, 2014   Reliant Renal Care, Inc. ... Home Choice TM Training Center at 650 ... passing all regulatory requirements without any deficiencies, our state-of- ... admitting patients. The Center focuses on the unique needs ... in the comfort of their home. The open-access facility ...
Breaking Medicine Technology:Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 2Nanotechnology Venture Targets Arterial, Heart and Kidney Diseases 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6A New Choice For Dialysis Patients In Bessemer 2
(Date:10/18/2014)... Dwight D. Im, M.D., FACOG, Director ... The National Institute of Robotic Surgery at Mercy ... world to successfully perform a minimally-invasive hysterectomy via ... Driver, developed by Intuitive Surgical, Inc. (ISRG). , ... and Drug Administration (FDA) clearance for use in ...
(Date:10/18/2014)... Recently, BamboofloorChina.com, one of the most distinguished bamboo ... assortment of bamboo floorings to its website. For ... worldwide clients now, up to 29 percent off. , ... for sale now; most of the company’s experts have been ... than 100 different kinds of elegant bamboo products on its ...
(Date:10/18/2014)... of Neuropsychopharmacology (ECNP) is pleased to announce that the ... Swaab, for his book, We are our Brains: From ... Media Award recognises outstanding contributions to destigmatising disorders of ... € 5,000. , The ECNP Media Award was established ... better understanding of the complexity and impact of disorders ...
(Date:10/18/2014)... One major trend upcoming in this ... which are making efforts to encourage people to donate ... organ donation process more transparent and easy. , Analysts ... to grow at a CAGR of 16.85 percent over ... the major drivers in the market is an increase ...
(Date:10/18/2014)... For the second time in less than a month, ... facing US businesses. On September 23rd, the warning ... employees. And now, according to this Reuters report , ... for US businesses about possible cyber espionage attacks by a ... high-value information.” , “With the constant stream of headlines ...
Breaking Medicine News(10 mins):Health News:National Recognized Gynecologic Oncologist Dr. Dwight Im World's First to Perform Surgery Using New FDA Cleared Single Site Wristed Needle Driver Technology 2Health News:National Recognized Gynecologic Oncologist Dr. Dwight Im World's First to Perform Surgery Using New FDA Cleared Single Site Wristed Needle Driver Technology 3Health News:Brand New Bamboo Floorings Now Unveiled By BamboofloorChina.com, A Distinguished Supplier In The Market 2Health News:Dick Swaab wins the 2014 ECNP Media Award 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4Health News:Another FBI Cyber Attack Warning for US Businesses 2Health News:Another FBI Cyber Attack Warning for US Businesses 3Health News:Another FBI Cyber Attack Warning for US Businesses 4
... Phase II for melanoma, to begin Phase II for breast ... cancer ... today at 9:00 a.m. EDT -, BRANFORD, Conn., April 22 CuraGen Corporation,(Nasdaq: ... the quarter ended March 31, 2008, CuraGen reported a net loss,of $6.8 million, or ...
... China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical,Group (NYSE: ... of,branded generic pharmaceuticals and manufacturer of the ... announced that it has,signed a definitive agreement ... Wuhu,Zhong Ren Pharmaceutical Co. Ltd. for a ...
... for the Service,Employees International Union claimed in an ... other acts of intimidation against,officers, directors and staff ... nothing more than "free speech.", A temporary ... Court Commission Jon Rantzman remains in effect today. ...
... treatment with drug 5-fluorouracil, study says , , MONDAY, April ... used chemotherapy drug causes memory problems and other cognitive ... brain," a new study found. , Up to 50 ... problems a year after chemotherapy treatment ended, according to ...
... DANVILLE, PA. Hearing repeated stories of suffering from ... workers, a new Geisinger-led study suggests. , In a ... Social Work Practice, Geisinger Senior Investigator Joseph Boscarino, PhD, ... and secondary trauma among 236 New York City social ...
... Appointed to Board ... of Directors, CINCINNATI, April 21, 2008 ... (Jack) F. Smith (70),will retire from the board following P&G,s April board meeting ... to:, http://www.prnewswire.com/mnr/pg/32757/ Mr. Smith has served on the board since 1995 ...
Cached Medicine News:Health News:CuraGen Reports First Quarter 2008 Financial Results 2Health News:CuraGen Reports First Quarter 2008 Financial Results 3Health News:CuraGen Reports First Quarter 2008 Financial Results 4Health News:CuraGen Reports First Quarter 2008 Financial Results 5Health News:CuraGen Reports First Quarter 2008 Financial Results 6Health News:Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd. 2Health News:SEIU Claims Right of 'Free Speech' to Stalk, Harass, and Threaten Registered Nurses According to the California Nurses Association 2Health News:Common Chemotherapy Drug Linked to Memory Problems 2Health News:Common Chemotherapy Drug Linked to Memory Problems 3Health News:Procter & Gamble Announces Board Changes 2
Button shape tip, round serrated handle, dull finish, overall length 130 mm....
... EX is a rigid gas lens with ... specific characteristics as hard contact lens, it ... excellent performance against astigmatism. The key feature ... combination of fluoromethacrylate, Siloxanylmethacrylate and methacrylic acid, ...
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: